Barclays PLC Has $157,000 Position in INmune Bio, Inc. (NASDAQ:INMB)

Barclays PLC grew its position in INmune Bio, Inc. (NASDAQ:INMB) by 601.9% in the third quarter, HoldingsChannel.com reports. The fund owned 29,044 shares of the company’s stock after buying an additional 24,906 shares during the quarter. Barclays PLC’s holdings in INmune Bio were worth $157,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of INMB. CVI Holdings LLC acquired a new position in INmune Bio during the 2nd quarter valued at about $5,260,000. Praetorian PR LLC raised its stake in INmune Bio by 61.0% during the 3rd quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock worth $4,209,000 after buying an additional 295,800 shares during the period. Marshall Wace LLP lifted its holdings in shares of INmune Bio by 332.1% during the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after purchasing an additional 89,091 shares in the last quarter. State Street Corp increased its stake in INmune Bio by 35.1% during the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock worth $1,220,000 after purchasing an additional 58,838 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in INmune Bio during the 3rd quarter worth approximately $249,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on INMB shares. Raymond James started coverage on INmune Bio in a research report on Friday, September 27th. They set an “outperform” rating and a $18.00 price objective for the company. Alliance Global Partners assumed coverage on shares of INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 target price for the company.

INmune Bio Price Performance

Shares of NASDAQ:INMB opened at $7.67 on Thursday. INmune Bio, Inc. has a one year low of $4.32 and a one year high of $14.74. The company has a market cap of $170.06 million, a price-to-earnings ratio of -3.52 and a beta of 1.78. The firm has a 50 day simple moving average of $5.20 and a 200 day simple moving average of $6.06.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Thursday, October 31st. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.11). During the same quarter last year, the company posted ($0.48) earnings per share. As a group, analysts expect that INmune Bio, Inc. will post -2.24 EPS for the current year.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.